OTCPK:NEPTF - Post by User
Post by
gwrbion Oct 13, 2011 5:07pm
400 Views
Post# 19147075
Conference call
Conference call
The call came in very handy. The results as announced left a lot of questions.
The $1M non-cash accounting charge for the stock-based compensation is a GAAP reality. Add that back, and everyone would be happy with the results. (If the SP stays down at $2.40 or less, this may be reversed next quarter)
The Acasti R&D costs are also an expensive reality for the next 12-18 months.
$20M in consolidated cash - which is a significant strength.
Strong confidence in future sales growth, but at lower pricing (which hopefully includes lower production costing as well).
Production capacity continues to increase.
And Tina's hope for a clinical trial completion for CaPre within 12 months.
I am assuming everyone but Scan and Boardwalk will feel a little better after hearing the phone call.
(admittedly, the French accent thing is a little problematic . ....)